Developing transcriptomic biomarkers for TAVO412 utilizing next generation sequencing analyses of preclinical tumor models
IntroductionTAVO412, a multi-specific antibody targeting epidermal growth factor receptor (EGFR), mesenchymal epithelial transition factor (c-Met), and vascular endothelial growth factor A (VEGF-A), is undergoing clinical development for the treatment …